radRounds Radiology Network

Connecting Radiology | Enabling collaboration and professional development

DaTscan Approved for Imaging Neurodegenerative Movement Disorders

(DIAGNOSTIC IMAGING) -- FDA Approves DaTscan to Assist in Evaluation of Neurodegenerative Movement Disorders


By Sara Michael

GE Healthcare announced recently that the FDA has approved the first imaging agent to help physicians in evaluating neurodegenerative movement disorders.

The FDA approved ioflupane I 123 injection (DaTscan), a radiopharmaceutical agent intended for use with single photon emission computed tomography (SPECT) imaging, for the detection of dopamine transporters in the brains of adult patients with suspected parkinsonian syndromes.


See full article and related articles at DiagnosticImaging.com

This article was republished with permission from CMPMedica, LLC

Views: 149

Comment

You need to be a member of radRounds Radiology Network to add comments!

Join radRounds Radiology Network

Sponsor Ad

© 2019   Created by radRounds Radiology Network.   Powered by

Badges  |  Report an Issue  |  Terms of Service